The Top 10 Healthcare - Genomics & Precision Medicine Stocks
143 stocks in the theme · theme 1-month +10.1% · as of 2026-10-30
Healthcare - Genomics & Precision Medicine is bouncing back: its median constituent jumped 3.1% over the past week after falling 6.1% over the prior three months, with 69% of its members advancing. Companies in gene therapy, genetic testing, and personalized medicine platforms.
Below are the 10 largest Healthcare - Genomics & Precision Medicine stocks by market capitalization, led by AZN (AstraZeneca PLC) at $243.3B. Each is shown with its 1-month, 3-month, and year-to-date performance, relative-strength rank, and recent price action — a snapshot of where the money and momentum sit in the theme today.
These are the recognizable leaders, not micro-cap lottery tickets: ranking by market cap surfaces the companies with the scale, liquidity, and institutional ownership to actually represent the theme. Use the relative-strength column to separate the names outperforming the broad market from those just along for the ride.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease…
AZN (AstraZeneca PLC) commands a $243.3B market cap. Within the theme it sits in the Precision Medicine Platforms sub-group. A +18.4% one-month move shows buyers in control. Relative strength sits mid-pack at 76. Over longer windows it's +18.2% in three months and +1.9% year-to-date.
#2. TMO — Thermo Fisher Scientific, Inc. · $242.1B
Life Sciences Tools & Services · Scientific Instruments — Life Sciences Focus · Public since 1972
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of…
TMO (Thermo Fisher Scientific, Inc.) commands a $242.1B market cap. Within the theme it sits in the Precision Medicine Platforms sub-group. The stock is up +6.8% over the past month — clear momentum. With RS at 86, it's outperforming the broad tape. Over longer windows it's +21.4% in three months and +17.6% year-to-date.
#3. DHR — Danaher Corporation · $150.5B
Life Sciences Tools & Services · Scientific Instruments — Life Sciences Focus · Public since 1978
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the…
DHR (Danaher Corporation) commands a $150.5B market cap. Within the theme it sits in the Precision Medicine Platforms sub-group. The stock is up +9.7% over the past month — clear momentum. An RS rank of 69 is middling — neither leader nor laggard. Over longer windows it's +17.6% in three months and +0.8% year-to-date.
#4. VRTX — Vertex Pharmaceuticals Inc · $127.9B
Biotechnology · Rare Disease Therapeutics — Small Molecule & Gene Therapy · Public since 1991
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain…
VRTX (Vertex Pharmaceuticals Inc) carries a $127.9B valuation. Within the theme it sits in the Gene Therapy & Gene Editing sub-group. The stock is up +10.3% over the past month — clear momentum. Relative strength is strong at 90 — it's outpacing most of the market. Over longer windows it's +18.7% in three months and +23.6% year-to-date.
#5. REGN — Regeneron Pharmaceuticals Inc · $75.7B
Biotechnology · Biotechnology — Large-Cap Therapeutics · Public since 1991
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular…
REGN (Regeneron Pharmaceuticals Inc) is a $75.7B name. Within the theme it sits in the Gene Therapy & Gene Editing sub-group. The stock is up +26.3% over the past month — clear momentum. An RS rank of 92 puts it among the market's leaders. Over longer windows it's +22.2% in three months and +19.5% year-to-date.
#6. NTRA — Natera, Inc. Common Stock · $59.1B
Life Sciences Tools & Services · Molecular Diagnostics — Liquid Biopsy & Prenatal · Public since 2015
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin…
NTRA (Natera, Inc. Common Stock) carries a $59.1B valuation. Within the theme it sits in the Genetic Testing & Diagnostics sub-group. The past month has been quiet — +1.4%. Relative strength is strong at 98 — it's outpacing most of the market. Over longer windows it's +53.2% in three months and +81.0% year-to-date.
#7. WAT — Waters Corp · $41.8B
Life Sciences Tools & Services · Scientific Instruments — Life Sciences Focus · Public since 1995
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end…
WAT (Waters Corp) carries a $41.8B valuation. Within the theme it sits in the Precision Medicine Platforms sub-group. The stock is up +8.7% over the past month — clear momentum. Relative strength is strong at 90 — it's outpacing most of the market. Over longer windows it's +23.5% in three months and +21.1% year-to-date.
#8. ILMN — Illumina Inc · $41.2B
Life Sciences Tools & Services · Genomics — Dna Sequencing Platforms · Public since 2000
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome…
ILMN (Illumina Inc) is a $41.2B name. Within the theme it sits in the Genetic Testing & Diagnostics sub-group. It's down -11.2% over the past month, lagging the theme's leaders. An RS rank of 98 puts it among the market's leaders. Over longer windows it's +19.1% in three months and +75.7% year-to-date.
#9. ALNY — Alnylam Pharmaceuticals, Inc. · $29.4B
Biotechnology · Rna Therapeutics — Antisense Oligonucleotides for Genetic Diseases · Public since 2004
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include…
ALNY (Alnylam Pharmaceuticals, Inc.) commands a $29.4B market cap. Within the theme it sits in the RNA Therapeutics sub-group. It's down -28.6% over the past month, lagging the theme's leaders. An RS rank of 25 flags relative underperformance. Over longer windows it's -25.1% in three months and -58.8% year-to-date.
#10. LH — Labcorp Holdings Inc. · $25.0B
Healthcare Services · Diagnostics — Clinical Laboratory Services · Public since 1988
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine…
LH (Labcorp Holdings Inc.) commands a $25.0B market cap. Within the theme it sits in the Genetic Testing & Diagnostics sub-group. The stock is up +18.6% over the past month — clear momentum. With RS at 91, it's outperforming the broad tape. Over longer windows it's +17.6% in three months and +43.6% year-to-date.